Cost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China

Cost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China

BackgroundThe phase III NAPOLI-3 trial, which upgraded FOLFIRINOX (leucovorin, fluorouracil, irinotecan and oxaliplatin) to NALIRIFOX (liposomal irinotecan, oxaliplatin, leucovorin, and fluorouracil), demonstrated the superiority of NALIRIFOX over GEMNABP (gemcitabine and nab-paclitaxel) as the firs...

Full description

Saved in:
Bibliographic Details
Main Authors: Zuojuan Xiang, Ling Ma, Zhengxiong Li, Yingzhou Fu, Yong Pan
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Pharmacology
Subjects:
metastatic pancreatic cancer
cost-effectiveness
FOLFIRINOX
NALIRIFOX
GEMNABP
liposomal irinotecan
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1488645/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items